|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
ALTIMMUNE CHIEF SCIENTIFIC OFFICER TO PRESENT
AT TWO PREMIER VACCINE CONFERENCES
Gaithersburg, Maryland – Oct. 12, 2015- Altimmune, Inc., (formerly Vaxin Inc.) a clinical stage immunotherapy
and vaccine company, today announced that Chief Scientific Officer M. Scot Roberts, PhD, will present at two
premier vaccine conferences in the coming weeks. The first is Bacillus ACT 2015, the international conference on
Bacillus anthracis, B. ceres & B. thuringiensis, to be held later this month in New Delhi, India. The second is
Vaccines R&D-2015, presented by the United Scientific Group, which takes place in Baltimore, MD in early
November. Both venues will feature scientists from industry, academia, government labs and agencies, and non-
profit organizations who will gather to discuss new research discoveries and influential therapies, and share best
practices relating to vaccine development.
Vaccines R&D-2015, Nov. 2-4
Paper Title: “The right fit: Matching the vaccine platform to the disease indication”.
Co-Authors: Bertrand Georges, Vyjayanthi Krishnan, James Francis, Jianfeng Zhang, Katie Anderson,
Christine Shoemaker, Ray Feng, and M. Scot Roberts.
Abstract
Selection of a particular vaccine platform technology can have an important impact on the ability to
meet current vaccine challenges. We are exploiting two independent and complementary platform
technologies to develop vaccines and immunotherapies for influenza, chronic hepatitis B, anthrax and
cancer. RespirVecTM is an intranasally administered replication-deficient adenoviral vector technology
that underlies our influenza and anthrax vaccine indications. For these indications, a strong humoral
response is required in order to neutralize the spread of the pathogen or the activity of the toxin,
respectively. Because RespirVec infects cells of the respiratory tract and expresses the vaccine antigen
intracellularly, other components of the immune system may also be activated including T cell, innate
immunity, and mucosal immunity as a result of the intranasal route of delivery. Humoral immunity is
expected to play a less important role in the immunotherapy of chronic infections and cancer. We are
developing immunotherapies for the treatment of chronic hepatitis B and cancer that are based on our
Densigen technology platform. DensigensTM are long synthetic peptides that are dense in helper and
cytotoxic T cell epitopes to overcome the HLA restriction issue that has limited peptide-based strategies
in the past. Densigens are also modified through the inclusion of an inert fluorocarbon tail that
preclinically facilitated aggregation of the peptide antigens to create a depot-like effect at the site of
injection and enhancing the immunogenicity of the antigens. By including peptide antigens representing
multiple conserved proteins, a broad immune response resistant to immune escape may be achieved.
About Altimmune
Altimmune is a clinical stage biotechnology company developing next-generation immunotherapeutics and vaccines to
address significant public health and biodefense needs. By leveraging specific attributes of its two independent and
complementary platform technologies, Altimmune can rapidly design product candidates against a wide range of
disease targets, including respiratory diseases, chronic infections, and cancer. Our DensigenTM T-cell platform
technology is uniquely suited to direct the immune response against traditionally difficult disease targets, including
chronic infections and cancer, by directing an individual’s immune system against multiple target antigens instead of
just one. Altimmune’s RespirVecTM platform utilizes convenient needle-free intranasal delivery to achieve broad
immunity against disease pathogens more rapidly than conventional vaccines. Altimmune’s product candidates are
easily manufactured, highly stable, and provide a safe, effective alternative to current products. www.altimmune.com.
|
|
发表于 2015-10-13 23:43
